BIO vs OCSL · rev $651.0M vs P/E 20, $1.05B cap
BIO (BIO) versus Oaktree Specialty Lending Corp (OCSL) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Oaktree Specialty Lending Corp (OCSL) is a asset management company listed on US.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
OCSL does not have a complete income-statement cache yet.
BIO currently screens at market cap $0. OCSL currently screens at market cap $1.05B and trailing P/E 20.2.
Not investment advice. Open the BIO and OCSL stock pages for the full models.
Not investment advice.